IPSOGEN
LIVE

Serial Number

76373789

Owner

QIAGEN MARSEILLE

Attorney

Daniel M. Gurfinkel

Filing Date

Feb 20, 2002

Add to watchlist:

No watchlists yet
View on USPTO

IPSOGEN Trademark

Serial Number: 76373789 • Registration: 2958962

IPSOGEN is a trademark filed by QIAGEN MARSEILLE on February 20, 2002. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics). The application is currently registered and active.

Owner Contact Info

QIAGEN MARSEILLE (5 trademarks)

LUMINY BIOTECH ENTREPRISES, CASE 923
MARSEILLE 13288 CED , FR

Entity Type: 03

QIAGEN GMBH (210 trademarks)

HILDEN D-4010 , DE

Entity Type: 03

IPSOGEN (10 trademarks)

232 boulevard Sainte-Marguerite
F-13273 Marseille Cedex 09 , FR

Entity Type: 03

Trademark Details

Filing Date

February 20, 2002

Registration Date

June 7, 2005

Published for Opposition

March 15, 2005

Goods & Services

[ Information processing devices, namely, computer keyboards, mouse, monitors, readers, data processing equipment, compact disc players, optical character readers, computer memories, printers for use with computers, processors; computer programs and software for stockage, management, and analysis of biological information ]

Biological reagents for diagnoses and for identification of biological systems [ ; pharmaceutical products, namely, preparations, chemical preparations and chemico-pharmaceutical preparations for treating illnesses, namely, genetic and infectious illnesses namely, acute leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia, AML, acute monocytic leukemia, AML, acute promyelocytic leukemia, APL, adenocarcinoma, adenocarcinoma lung cancer, adenocystic carcinoma, adenoid cystic breast cancer, adenoid cystic arcinoma, adrenal gland cancer, advanced breast cancer, aggressive breast cancer, ameloblastoma, anal, anus cancer; angiosarcoma, appendix cancer, appendiceal cancer, astrocytoma, arrett's esophagus, bartholin gland cancer, basal cell carcinoma, basal cell skin cancer, B-cell lymphoma, bilateral breast cancer, bile duct cancer, bladder cancer, bladder metastases, bone cancer, bone marrow transplantation, Bowen's disease, bone metastases, borderline ovarian cancer, brain metastases, brain tumor, brainstem glioma, breast cancer, breast reconstruction, bronchial cancer, bronchioalveolar lung cancer, buttock cancer, cancer of unknown primary site, CUPS, cancer prevention, carcinoma of unknown primary, carcinoid, carcinoid syndrome, carcinoid tumor, carcinosarcoma, cavernous sinus cancer, cecum cancer, central nervous system lymphoma, centrocytic lymphoma, cerebral astrocytoma, cervix cancer, cervical cancer, chest tumors, mediastinum tumors, chiasmal glioma, childhood cancers, chondroma, intracranial, chordoma, chondrosarcoma, chorioadenoma destruens, choroids plexus carcinoma, choroidal melanoma, chronic leukemia, chronic lymphocytic leukemia, CLL, chronic myelogenous leukemia, CML, clear cell ovarian cancer, clear cell sarcoma, CNS lymphoma, colon cancer, adenocarcinoma of the colon, adenomatous polyps, polyps, colorectal cancer, craniopharyngioma, cutaneous T-cell lymphoma, DCIS - ductal carcinoma in situ, dermatofibrosarcoma protuberans, desmoidtumor, desmoplastic tumor, diffuse lymphoma, diffuse, large-cell lymphoma, ductal carcinoma in situ, DCIS, duodenalcancer dysgerminoma, early stage prostate cancer, endocrine cancer, endometrial cancer, endometrial stromal sarcoma, ependymoma, esophagus cancer, esophageal cancer, esophagus cancer of the gastroesophageal junction, esthesioneuroblastoma, Ewing's sarcoma, extensive stage small cell lung cancer, extrahepatic bile duct cancer, extraskeletal chondrosarcoma, extraskeletal Ewing's sarcoma, extraskeletal osteosarcoma, eye metastases, eye cancer, fallopian tube cancer, fibrosarcoma, fibrous histiocytoma, follicular lymphoma, follicular, small-cleaved cell lymphoma, gallbladder cancer, gastric cancer, gastrinoma, gastro-esophageal, GE junction, cancer, gastrointestinal lymphoma, GE junction esophageal cancer, germ cell tumor, gestational trophoblastic disease, giant cell bone tumor, glioblastoma, glioma, gliomatosis, granular lymphocytic lymphoma, granulocytic leukemia, granulosa cell ovarian cancer, hairy cell leukemia, head and neck cancer, hemangioendothelioma, hemangiopericytoma, hepatocelluar carcinoma, high-grade lymphoma, high-risk breast cancer, histiocytoma, malignant, Hodgkin's disease, Hodgkin's disease in pregnancy, hormone-refractory prostate cancer, in situ breast cancer, insulinoma, intermediate-grade lymphoma, intraocular melanoma, invasive lobular breast cancer, islet cell pancreatic cancer, Kaposi's sarcoma, kidney cancer, krukenberg tumor, large-cell lung cancer, large-cell lymphoma, large-cell, diffuse lymphoma, larynx cancer, laryngeal cancer, leiomyosarcoma, lentigo maligna, leukemia, linitis plastica, limited stage small cell lung cancer, lip cancer, liposarcoma, liver cancer, recurrent liver cancer, undifferentiated liver cancer, lobular carcinoma in situ, LCIS, lobular hyperplasia low-grade lymphoma, lung cancer, non-small cell lung cancer, epidermoid carcinoma, large cell carcinoma, squamous cell carcinoma, spindal cell variant, pancoast tumors, superior sSulcus tumors, undifferentiated carcinoma, lung metastases, lymph node excision, lymphangitic metastasis, lymph node metastases, lymphoblastic leukemia, lymphoblastic lymphoma, lymphocytic lymphoma, lymphoma, non-Hodgkin's lymphoma, malignant ascites, malignant hemangiopericytoma, malignant fibrous histiocytoma, malignant peripheral nerve sheath tumor, malignant pleural effusion, malignant schwannoma, MALT lymphoma, mantle cell lymphoma, medlastinal tumor, medulloblastoma, melanoma, meningeal cancer, meningeal metastases, meningioma, merkel cell carcinoma, merkel cell skin cancer, mesothelioma, mesenchymal chondrosarcoma, metastatic melanoma, mixed mullerian tumor, mucinous carcinoma, multiple myeloma, muscle-invasive bladder tumor, mycosis fungoides, myelodysplasia, myelodysplastic syndrome, myeloma, Bence-Jones, myeloproliferative disorder, nail/nail bed cancer, nasal cavity cancer, nasopharynx cancer, neck, radical dissection, neoplastic meningitis, nerve sheath tumors, neuroblastoma, neuroendocrine tumor, adenosquamous carcinoma, adenocarcinoma, ocular melanoma, olfactory cancer, oligodendroglioma, optic glioma, oral cancer, orbital lumphoma, orophaiynx cancer, osteogenic sarcoma, osteosarcoma, ovarian cancer, Pagets disease of the breast, pancreatic cancer, recurrent pancreatic cancer, borderline pancreatic tumors, mucinous cystic tumor with dysplasia, intraductal papillary mucinous tumor with dysplasia, pseudopapillary solid tumor, islet cell tumors, gastrinoma, paraganglioma, paranasal sinus cancer, paraneoplastic syndromes, parathyroid cancer, parotid gland cancer, pelvic tumor, penis cancer, periampullary cancer, pericardial effusion, peripheral nerve sheath tumor, peripheral T-cell lymphoma, peritoneal cancer, extraovarian serous carcinoma, extraovarian peritoneal serious papillary carcinoma, serous surface carcinoma of the peritoneum, serous surface papillary carcinoma, papillary serous carcinoma of the peritoneum, multiple focal peritoneal papillary carcinoma, primary peritoneal papillary serous adenocarcinoma, peritoneal carcinomatosis, pheochromocytoma, pinealoma, pineoblastoma, plasmacytoma, pleura cancer, pleura metastases, preleukemia, primary central nervous system lymphoma, primitive neuroctodermal tumor, PNET, plolymphocytic leukemia, promyelocytic leukemia, prophylactic mastectomy, prostate cancer, prostatic intraepithelial neoplasia, PIN, PSA, pseudomyxoma peritonei, rectal cancer, recurrent colon cancer, recurrent colorectal cancer, recurrent lung cancer, recurrent melanoma, recurrent ovarian cancer, recurrent prostate cancer, recurrent rectal cancer, relapsed lymphoma, renal cell carcinoma, renal pelvis cancer, retinoblastoma, rhabdomyosarcoma, Richters syndrome, rising PSA as an indication of recurrent prostate cancer, salivary gland cancer, sarcoma of bone, sarcomatoid carcinoma; sebaceous carcinoma, sezary syndrome, sinus, cavernous, sinus cancer, skin cancer, skin metastases, small cell bladder cancer, small cell lung cancer, small cleaved cell lymphoma, small intestine cancer, soft tissue lymphoma, soft tissue sarcoma, synovial sarcoma, spinal cord cancer, spindle cell thyroid cancer, squamous cell cancer, non-skin, squamous cell lung cancer, squamous cell skin cancer, stem cell transplantation, stomach cancer, superficial bladder cancer, sweat glands cancer, T-cell leukemia, T-cell lymphoma, cutaneous, testicular cancer, testis cancer, thalamu, thalamic, brain tumor, thymoma, thymus gland cancer, thyroid cancer, thyroid lymphoma, tongue cancer, tongue base cancer, transitional cell cancer of renal pelvis, transitional cell cancer of the ureter, unknown primary cancer, ureter cancer, urethra cancer, uterine cancer, uterine sarcoma, vagina cancer, vocal cord cancer, vulva cancer, Waldenstrom's macroglobulinemia, Warthin's tumor, Wilms' tumor, Zollinger-Ellis syndrome ]

Filing History

POST REGISTRATION ACTION MAILED - SEC. 8 & 9
Sep 13, 2025 PR89
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Sep 13, 2025 APRE
TEAS SECTION 8 & 9 RECEIVED
May 14, 2025 E89R
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Jun 7, 2024 REM2
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Sep 24, 2020 ASGN
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
Dec 15, 2015 NAS8
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Dec 15, 2015 RNL1
REGISTERED - SEC. 9 GRANTED/CHECK RECORD FOR SEC. 8
Dec 15, 2015 9G8P
REGISTERED - PARTIAL SEC. 8 (10-YR) ACCEPTED
Dec 15, 2015 8PRT
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Dec 15, 2015 APRE
TEAS SECTION 8 & 9 RECEIVED
Oct 19, 2015 E89R
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Oct 7, 2015 ASGN
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Jul 14, 2011 NA85
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Jul 14, 2011 C15A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jul 14, 2011 APRE
TEAS SECTION 8 & 15 RECEIVED
Jun 2, 2011 E815
REGISTERED-PRINCIPAL REGISTER
Jun 7, 2005 R.PR
PUBLISHED FOR OPPOSITION
Mar 15, 2005 PUBO
NOTICE OF PUBLICATION
Feb 23, 2005 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Oct 21, 2004 PREV
ASSIGNED TO LIE
Oct 19, 2004 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 12, 2004 CNSA
AMENDMENT FROM APPLICANT ENTERED
Oct 7, 2004 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 22, 2004 CRFA
PAPER RECEIVED
Sep 22, 2004 MAIL
NON-FINAL ACTION MAILED
Jun 4, 2004 CNRT
Sec. 1(B) CLAIM DELETED
Apr 26, 2004 1.BD
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 26, 2004 CRFA
PAPER RECEIVED
Apr 26, 2004 MAIL
NON-FINAL ACTION MAILED
Oct 23, 2003 CNRT
CASE FILE IN TICRS
Sep 13, 2003 CFIT
LETTER OF SUSPENSION MAILED
Feb 21, 2003 CNSL
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 13, 2002 CRFA
PAPER RECEIVED
Dec 13, 2002 MAIL
NON-FINAL ACTION MAILED
Jun 19, 2002 CNRT
UNRESPONSIVE/DUPLICATE PAPER RECEIVED
Jun 17, 2002 UNPR
ASSIGNED TO EXAMINER
Jun 14, 2002 DOCK
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Mar 15, 2002 AMPX
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 15, 2002 CRFA
PAPER RECEIVED
Mar 15, 2002 MAIL